Taken together, these results indicate that in cetuximab-resistant HNSCC cells, chronic exposure to cetuximab leads to an inflammatory signature, resulting in the chronic activation of STAT1 and its subsequent degradation through polyubiquitination. This evidence concerns the gene STAT1 and head and neck squamous cell carcinoma.